CardiovascularORALGeneric
NIKITA
PITAVASTATIN SODIUM
Standard Dose
EQ 2MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview NIKITA is listed in Drugs@FDA under application 209875 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient PITAVASTATIN SODIUM Form and strength TABLET;ORAL - EQ 2MG BASE Sponsor LUPIN LTD Submission history Latest submission status date: 2023-10-30 00:00:00.
Structured Monograph
Clinical summary
Approval overview NIKITA is listed in Drugs@FDA under application 209875 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient PITAVASTATIN SODIUM Form and strength TABLET;ORAL - EQ 2MG BASE Sponsor LUPIN LTD Submission history Latest submission status date: 2023-10-30 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.